Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

TORREY phase 2 study of seralutinib in pulmonary arterial hypertension (PAH): Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment

Wednesday, May 22, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The TORREY phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH) has shown promising results, with improvements in circulating biomarkers associated with proliferation, inflammation, and fibrosis. This suggests that seralutinib may be an effective treatment option for PAH. The study highlights the importance of monitoring these biomarkers during treatment.
Price reaction · baseline $0.67 (2024-05-21 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
-4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Improvement in circulating biomarkers observed with treatment.
  • Phase 2 study indicates potential efficacy of seralutinib.
  • Focus on pulmonary arterial hypertension (PAH) treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

TORREY phase 2 study of seralutinib in pulmonary arterial hypertension (PAH): Circulating biomarkers of proliferation, inflammation and fibrosis improve with treatment
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the TORREY study about?

The TORREY study investigates the effects of seralutinib in patients with pulmonary arterial hypertension.

What improvements were observed in the study?

The study reported improvements in circulating biomarkers related to proliferation, inflammation, and fibrosis.

What condition is seralutinib targeting?

Seralutinib is targeting pulmonary arterial hypertension (PAH) in the study.

What phase is the TORREY study?

The TORREY study is a phase 2 clinical trial.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib pulmonary arterial hypertension PAH TORREY study biomarkers
Last updated: May 22, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →